145 related articles for article (PubMed ID: 14740604)
21. Physicians say generic AIDS drugs don't threaten R&D.
AIDS Policy Law; 2002 Mar; 17(6):4. PubMed ID: 12004757
[No Abstract] [Full Text] [Related]
22. Half the 14 million people in poorer countries who need antiretrovirals get them.
Gulland A
BMJ; 2011 Nov; 343():d7576. PubMed ID: 22108274
[No Abstract] [Full Text] [Related]
23. Global AIDS conference finds the issue is cash.
Cullinan K
Bull World Health Organ; 2002; 80(9):761-2. PubMed ID: 12378299
[No Abstract] [Full Text] [Related]
24. HIV/AIDS: Latin America & Caribbean. Brazil: ten years after.
Cohen J
Science; 2006 Jul; 313(5786):484-7. PubMed ID: 16873654
[No Abstract] [Full Text] [Related]
25. Trade systems in less-developed countries.
Kamal Smith M; 't Hoen E
Lancet; 2001 May; 357(9268):1624. PubMed ID: 11386324
[No Abstract] [Full Text] [Related]
26. Crunch time for funding of universal access to antiretroviral treatment for people with HIV infection.
Maher D; von Schoen-Angerer T; Cohn J
Int J Clin Pract; 2011 Aug; 65(8):824-7. PubMed ID: 21762306
[No Abstract] [Full Text] [Related]
27. "No turning back" on cheap AIDS drugs for poor nations, UN vows.
Silversides A
CMAJ; 2003 Nov; 169(10):1067. PubMed ID: 14609992
[No Abstract] [Full Text] [Related]
28. Generic HIV drugs will widen US treatment net.
Maxmen A
Nature; 2012 Aug; 488(7411):267. PubMed ID: 22895314
[No Abstract] [Full Text] [Related]
29. Therapies. The high cost of poverty.
Cohen J
Science; 2002 Jun; 296(5577):2324. PubMed ID: 12089424
[No Abstract] [Full Text] [Related]
30. WHO pulls three more AIDS drugs from list.
Fleck F
BMJ; 2004 Aug; 329(7462):368. PubMed ID: 15310604
[No Abstract] [Full Text] [Related]
31. The AIDS response catalysing economic and social transformation: the importance of local pharmaceutical production.
Sidibé M
Antivir Ther; 2014; 19 Suppl 3():3-4. PubMed ID: 25310132
[No Abstract] [Full Text] [Related]
32. Universal access to HIV/AIDS treatment: promise and problems.
Jaffe HW
JAMA; 2008 Aug; 300(5):573-5. PubMed ID: 18677030
[No Abstract] [Full Text] [Related]
33. Access denied to essential medicines in developing world.
Ahmad K
Lancet Infect Dis; 2002 Dec; 2(12):711. PubMed ID: 12467674
[No Abstract] [Full Text] [Related]
34. The danger of in-kind drug donations to the Global Fund.
Baker BK; Ombaka E
Lancet; 2009 Apr; 373(9670):1218-21. PubMed ID: 18848353
[No Abstract] [Full Text] [Related]
35. Production of low cost AIDS drugs to continue in Brazil.
Reprod Health Matters; 2001 Nov; 9(18):178. PubMed ID: 11803899
[No Abstract] [Full Text] [Related]
36. HIV/AIDS. The great funding surge.
Cohen J
Science; 2008 Jul; 321(5888):512-9. PubMed ID: 18653876
[No Abstract] [Full Text] [Related]
37. Production of antiretroviral drugs in middle- and low-income countries.
Pinheiro Edos S; Brüning K; Macedo MF; Siani AC
Antivir Ther; 2014; 19 Suppl 3():49-55. PubMed ID: 25310755
[TBL] [Abstract][Full Text] [Related]
38. International. Rights group: U.S. blocking access to generic AIDS drugs.
AIDS Policy Law; 2004 Apr; 19(7):1, 4. PubMed ID: 15124593
[No Abstract] [Full Text] [Related]
39. U.S. researcher starts treatment fund in Uganda: interview with David Bangsberg, M.D., M.P.H.
Bangsberg D
AIDS Treat News; 2004 Jun; (402):3-5. PubMed ID: 15272457
[TBL] [Abstract][Full Text] [Related]
40. TAC, MSF import generic AIDS drugs into South Africa.
IAPAC Mon; 2002 Mar; 8(3):73. PubMed ID: 12064307
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
